Ginkgo Bioworks (DNA) vs Helus Pharma (HELP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Helus Pharma (HELP) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 73.1% versus a loss of 22.6%. Over five years, HELP leads with a -86.0% price change compared with -97.6% for DNA. Helus Pharma is the larger company by market cap ($763.5 million vs $750.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | HELP |
|---|---|---|
| Share price | $11.14 | $10.45 |
| Market cap | $750.26M | $763.48M |
| 1-day change | -2.87% | -0.57% |
| YTD return | +38.03% | +28.48% |
| 1-year return | -22.60% | +73.15% |
| 5-year return | -97.59% | -85.96% |
| EPS (TTM) | $-5.06 | $-4.15 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $15.15 |
| 52-week low | $5.37 | $3.76 |
| Distance from 52-week high | -38.85% | -31.02% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -37.17% | +281.15% |
| Average volume | 1.77M | 1.78M |
| Shares outstanding | 55.38M | 73.06M |
| Employees | 485 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HELP has outperformed DNA by 95.8 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Helus Pharma
HELP stock →Helus Pharma Inc., doing business as Helus Pharma, operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions. It develops HLP003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder; and HLP004, a deuterated N, N-dimethyltryptamine, which is in phase 2 clinical trial for treating generalized anxiety disorders.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
DNA vs HELP FAQ
Which is bigger, Ginkgo Bioworks or Helus Pharma?
Helus Pharma (HELP) is larger, with a market capitalization of $763.48M compared with $750.26M for Ginkgo Bioworks (DNA).
Which stock has performed better over the past year, DNA or HELP?
HELP returned +73.15% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Helus Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Ginkgo Bioworks and Biotechnology: Pharmaceutical Preparations for Helus Pharma.